Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis? 2015

M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
Rheumatology Unit, University of Verona. maurizio.rossini@univr.it.

Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D013167 Spondylitis, Ankylosing A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions. Ankylosing Spondylitis,Bechterew Disease,Marie-Struempell Disease,Rheumatoid Spondylitis,Spondylarthritis Ankylopoietica,Ankylosing Spondylarthritis,Ankylosing Spondyloarthritis,Bechterew's Disease,Spondylitis Ankylopoietica,Spondyloarthritis Ankylopoietica,Ankylosing Spondylarthritides,Ankylosing Spondyloarthritides,Bechterews Disease,Marie Struempell Disease,Spondylarthritides, Ankylosing,Spondylarthritis, Ankylosing,Spondylitis, Rheumatoid,Spondyloarthritides, Ankylosing,Spondyloarthritis, Ankylosing
D015535 Arthritis, Psoriatic A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor. Psoriasis Arthropathica,Psoriasis, Arthritic,Psoriatic Arthritis,Psoriatic Arthropathy,Arthritic Psoriasis,Arthropathies, Psoriatic,Arthropathy, Psoriatic,Psoriatic Arthropathies
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
January 2009, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
September 2010, Expert review of clinical immunology,
M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
March 2019, Rheumatology (Oxford, England),
M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
October 2013, Rheumatology (Oxford, England),
M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
June 2010, Core evidence,
M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
January 2010, Drugs of today (Barcelona, Spain : 1998),
M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
September 2020, Current medical research and opinion,
M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
January 2017, Clinical and experimental rheumatology,
M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
March 2022, Arthritis research & therapy,
M Rossini, and O Viapiana, and G Orsolini, and E Fracassi, and L Idolazzi, and D Gatti, and S Adami, and M Govoni
December 2016, The Journal of rheumatology,
Copied contents to your clipboard!